PNC Financial Services Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,156
| Closed | -$424K | – | 4804 |
|
|
2023
Q2 | $424K | Buy |
4,156
+60
| +1% | +$5.68K | ﹤0.01% | 1679 |
|
|
2023
Q1 | $372K | Sell |
4,096
-69
| -2% | -$4.05K | ﹤0.01% | 1736 |
|
|
2022
Q4 | $158K | Buy |
4,165
+69
| +2% | +$2.38K | ﹤0.01% | 2282 |
|
|
2022
Q3 | $103K | Sell |
4,096
-6
| -0.1% | -$166 | ﹤0.01% | 2520 |
|
|
2022
Q2 | $124K | Buy |
4,102
+60
| +1% | +$1.79K | ﹤0.01% | 2423 |
|
|
2022
Q1 | $132K | Sell |
4,042
-63
| -2% | -$1.87K | ﹤0.01% | 2536 |
|
|
2021
Q4 | $108K | Sell |
4,105
-6,007
| -59% | -$465K | ﹤0.01% | 2640 |
|
|
2021
Q3 | $1.02M | Sell |
10,112
-14
| -0.1% | -$1.64K | ﹤0.01% | 1183 |
|
|
2021
Q2 | $1.43M | Sell |
10,126
-68
| -0.7% | -$7.68K | ﹤0.01% | 1049 |
|
|
2021
Q1 | $1.01M | Sell |
10,194
-10
| -0.1% | -$1.17K | ﹤0.01% | 1152 |
|
|
2020
Q4 | $1.26M | Buy |
10,204
+33
| +0.3% | +$4.34K | ﹤0.01% | 1026 |
|
|
2020
Q3 | $990K | Sell |
10,171
-917
| -8% | -$115K | ﹤0.01% | 1051 |
|
|
2020
Q2 | $1.73M | Sell |
11,088
-258
| -2% | -$39.2K | ﹤0.01% | 829 |
|
|
2020
Q1 | $1.64M | Buy |
11,346
+300
| +3% | +$57.9K | ﹤0.01% | 786 |
|
|
2019
Q4 | $2.26M | Buy |
11,046
+982
| +10% | +$179K | ﹤0.01% | 781 |
|
|
2019
Q3 | $808K | Sell |
10,064
-24
| -0.2% | -$2.04K | ﹤0.01% | 1354 |
|
|
2019
Q2 | $952K | Hold |
10,088
| – | – | ﹤0.01% | 1304 |
|
|
2019
Q1 | $862K | Buy |
10,088
+39
| +0.4% | +$3.24K | ﹤0.01% | 1355 |
|
|
2018
Q4 | $565K | Buy |
10,049
+11
| +0.1% | +$672 | ﹤0.01% | 1492 |
|
|
2018
Q3 | $820K | Hold |
10,038
| – | – | ﹤0.01% | 1430 |
|
|
2018
Q2 | $352K | Hold |
10,038
| – | – | ﹤0.01% | 1858 |
|
|
2018
Q1 | $206K | Hold |
10,038
| – | – | ﹤0.01% | 2151 |
|
|
2017
Q4 | $284K | Buy |
10,038
+38
| +0.4% | +$1.06K | ﹤0.01% | 1990 |
|
|
2017
Q3 | $312K | Hold |
10,000
| – | – | ﹤0.01% | 1890 |
|
|
2017
Q2 | $316K | Hold |
10,000
| – | – | ﹤0.01% | 1862 |
|
|
2017
Q1 | $226K | Hold |
10,000
| – | – | ﹤0.01% | 2068 |
|
|
2016
Q4 | $218K | Hold |
10,000
| – | – | ﹤0.01% | 2068 |
|
|
2016
Q3 | $264K | Hold |
10,000
| – | – | ﹤0.01% | 1932 |
|
|
2016
Q2 | $198K | Buy |
+10,000
| New | +$194K | ﹤0.01% | 2091 |
|
Other funds holding RETA
PNC Financial Services Group's RETA Position: Q3 2023 in Review
PNC Financial Services Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4,156 shares — an estimated $424K sold.
PNC Financial Services Group first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $2.26M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- PNC Financial Services Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- PNC Financial Services Group sold 4,156 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $424K.
- PNC Financial Services Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- PNC Financial Services Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.26M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on PNC Financial Services Group's 13F filing for Q3 2023, filed 13 Nov 2023.